Forecasting The Future: 19 Analyst Projections For Biogen
Portfolio Pulse from Benzinga Insights
Over the past three months, 19 analysts have evaluated Biogen (NASDAQ:BIIB), with a mix of bullish and bearish opinions. The average 12-month price target is $274.32, down 2.86% from the previous average. Recent analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting varied sentiments about Biogen's future performance.
June 26, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have mixed views on Biogen, with recent actions including maintaining, raising, and lowering ratings and price targets. The average 12-month price target is $274.32, down 2.86% from the previous average.
The mixed analyst ratings and slight decrease in the average price target suggest a neutral short-term impact on Biogen's stock price. While some analysts are bullish, others have lowered their price targets, indicating uncertainty about the company's near-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100